Radioligand Therapeutics Market Seen Growing to $4.8 Billion by 2030
The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.
The global market for radioligand therapeutics in cancer treatment is poised for significant expansion, estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030, at a CAGR of 13.1%. Radioligand therapy (RLT), leveraging targeted ligands to deliver therapeutic radionuclides to cancer cells, is validated for treating advanced prostate cancer and neuroendocrine tumors.
Pluvicto (Lu-177 PSMA) and Lutathera (Lu-177 SSTR) have catalyzed commercial momentum, underpinning the approved market. RLT's benefits in selected patients are complemented by specialized infrastructure and focused management of treatment-related effects and radiation safety.
The sector is evolving rapidly with advancements in PSMA PET and SSTR PET, earlier-line settings, and combination regimens with standard care, broadening the eligible patient base. Although isotopes supply and specialized personnel constraints persist, especially outside leading centers, RLT's adoption is projected to increase across North America, Europe, and emerging markets through 2030.
Largely driven by Lutetium-177 products for near-term revenues, future growth is expected from alpha-emitter and novel platform programs. The report examines approved therapies like Pluvicto and Lutathera and pipeline assets targeting tumor-specific receptors such as GRPR.
Market segmentation covers product type, indication type, and end user, focusing on the North American region, where Novartis AG anchors the market with substantial sales, supported by reliable data. Elsewhere, RLT remains in an early stage, with limited commercial uptake and insufficient data for in-depth segment analysis.
The report delivers data for 2024 and estimates for 2025, with forecasts through 2030, and examines regulatory pathways, reimbursement frameworks, collaborations, and isotope production expansions.